Syncom Formulations (India)（524470）株式概要Syncom Formulations (India) Limited は、インドで医薬品製剤の製造、販売、マーケティングを行っている。 詳細524470 ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長0/6過去の実績5/6財務の健全性6/6配当金0/6報酬当社が推定した公正価値より66.5%で取引されている 過去1年間で収益は54.6%増加しました リスク分析リスクチェックの結果、524470 、リスクは検出されなかった。すべてのリスクチェックを見る524470 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₹Current Price₹16.02117.7% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture013b2016201920222025202620282031Revenue ₹12.8bEarnings ₹1.9bAdvancedSet Fair ValueView all narrativesSyncom Formulations (India) Limited 競合他社Fredun PharmaceuticalsSymbol: BSE:539730Market cap: ₹13.2bBeta DrugsSymbol: NSEI:BETAMarket cap: ₹14.1bSakar HealthcareSymbol: NSEI:SAKARMarket cap: ₹17.5bNGL Fine-ChemSymbol: BSE:524774Market cap: ₹17.5b価格と性能株価の高値、安値、推移の概要Syncom Formulations (India)過去の株価現在の株価₹16.0252週高値₹23.4652週安値₹10.21ベータ0.761ヶ月の変化19.02%3ヶ月変化25.65%1年変化-27.28%3年間の変化126.59%5年間の変化103.04%IPOからの変化965.97%最新ニュースReported Earnings • May 23Full year 2026 earnings released: EPS: ₹0.81 (vs ₹0.53 in FY 2025)Full year 2026 results: EPS: ₹0.81 (up from ₹0.53 in FY 2025). Revenue: ₹5.21b (up 12% from FY 2025). Net income: ₹764.4m (up 55% from FY 2025). Profit margin: 15% (up from 11% in FY 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹12.25, the stock trades at a trailing P/E ratio of 16.7x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 88% over the past three years.Reported Earnings • Feb 14Third quarter 2026 earnings released: EPS: ₹0.23 (vs ₹0.14 in 3Q 2025)Third quarter 2026 results: EPS: ₹0.23 (up from ₹0.14 in 3Q 2025). Revenue: ₹1.21b (down 5.4% from 3Q 2025). Net income: ₹189.1m (up 45% from 3Q 2025). Profit margin: 16% (up from 10% in 3Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth.Reported Earnings • Nov 13Second quarter 2026 earnings released: EPS: ₹0.18 (vs ₹0.16 in 2Q 2025)Second quarter 2026 results: EPS: ₹0.18 (up from ₹0.16 in 2Q 2025). Revenue: ₹1.27b (up 24% from 2Q 2025). Net income: ₹166.0m (up 49% from 2Q 2025). Profit margin: 13% (up from 11% in 2Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 26% per year, which means it is significantly lagging earnings growth.お知らせ • Oct 01Syncom Formulations (India) Limited Approves Appointment of Shri Ankit Kedarmal as Executive ChairmanSyncom Formulations (India) Limited at its AGM held on September 29, 2025, approved appointment of Shri Ankit Kedarmal as Executive Chairman and to approve the remuneration payable to him.お知らせ • Sep 04+ 2 more updatesSyncom Formulations (India) Limited to Report Q3, 2026 Results on Feb 14, 2026Syncom Formulations (India) Limited announced that they will report Q3, 2026 results on Feb 14, 2026最新情報をもっと見るRecent updatesReported Earnings • May 23Full year 2026 earnings released: EPS: ₹0.81 (vs ₹0.53 in FY 2025)Full year 2026 results: EPS: ₹0.81 (up from ₹0.53 in FY 2025). Revenue: ₹5.21b (up 12% from FY 2025). Net income: ₹764.4m (up 55% from FY 2025). Profit margin: 15% (up from 11% in FY 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹12.25, the stock trades at a trailing P/E ratio of 16.7x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 88% over the past three years.Reported Earnings • Feb 14Third quarter 2026 earnings released: EPS: ₹0.23 (vs ₹0.14 in 3Q 2025)Third quarter 2026 results: EPS: ₹0.23 (up from ₹0.14 in 3Q 2025). Revenue: ₹1.21b (down 5.4% from 3Q 2025). Net income: ₹189.1m (up 45% from 3Q 2025). Profit margin: 16% (up from 10% in 3Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth.Reported Earnings • Nov 13Second quarter 2026 earnings released: EPS: ₹0.18 (vs ₹0.16 in 2Q 2025)Second quarter 2026 results: EPS: ₹0.18 (up from ₹0.16 in 2Q 2025). Revenue: ₹1.27b (up 24% from 2Q 2025). Net income: ₹166.0m (up 49% from 2Q 2025). Profit margin: 13% (up from 11% in 2Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 26% per year, which means it is significantly lagging earnings growth.お知らせ • Oct 01Syncom Formulations (India) Limited Approves Appointment of Shri Ankit Kedarmal as Executive ChairmanSyncom Formulations (India) Limited at its AGM held on September 29, 2025, approved appointment of Shri Ankit Kedarmal as Executive Chairman and to approve the remuneration payable to him.お知らせ • Sep 04+ 2 more updatesSyncom Formulations (India) Limited to Report Q3, 2026 Results on Feb 14, 2026Syncom Formulations (India) Limited announced that they will report Q3, 2026 results on Feb 14, 2026お知らせ • Aug 11Syncom Formulations (India) Limited, Annual General Meeting, Sep 29, 2025Syncom Formulations (India) Limited, Annual General Meeting, Sep 29, 2025, at 14:00 Indian Standard Time.Reported Earnings • Aug 09First quarter 2026 earnings released: EPS: ₹0.21 (vs ₹0.11 in 1Q 2025)First quarter 2026 results: EPS: ₹0.21 (up from ₹0.11 in 1Q 2025). Revenue: ₹1.23b (up 41% from 1Q 2025). Net income: ₹157.5m (up 106% from 1Q 2025). Profit margin: 13% (up from 8.7% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 26% per year, which means it is significantly lagging earnings growth.お知らせ • Aug 08+ 1 more updateSyncom Formulations (India) Limited Announces CFO ChangesSyncom Formulations (India) Limited announced that at its board meeting held on August 08, 2025, noted and accepted the resignation of Shri Ankit Kedarnal Bankda from the position of Chief Financial Officer (CFO), with effect from the close of business hours on August 08, 2025. The company approved the appointment of Shri Rahul Vijay Bankda as Chief Financial Officer (CFO) of the Company, with effect from August 09, 2025.お知らせ • Aug 02Syncom Formulations (India) Limited to Report Q1, 2026 Results on Aug 08, 2025Syncom Formulations (India) Limited announced that they will report Q1, 2026 results on Aug 08, 2025New Risk • May 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Reported Earnings • May 21Full year 2025 earnings released: EPS: ₹0.57 (vs ₹0.27 in FY 2024)Full year 2025 results: EPS: ₹0.57 (up from ₹0.27 in FY 2024). Revenue: ₹4.82b (up 83% from FY 2024). Net income: ₹494.3m (up 95% from FY 2024). Profit margin: 10% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 31% per year whereas the company’s share price has increased by 33% per year.Valuation Update With 7 Day Price Move • May 16Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹17.51, the stock trades at a trailing P/E ratio of 42x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 92% over the past three years.お知らせ • May 13Syncom Formulations (India) Limited to Report Q4, 2025 Results on May 19, 2025Syncom Formulations (India) Limited announced that they will report Q4, 2025 results on May 19, 2025Valuation Update With 7 Day Price Move • Mar 24Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹18.25, the stock trades at a trailing P/E ratio of 43.8x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 67% over the past three years.Valuation Update With 7 Day Price Move • Mar 10Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹17.12, the stock trades at a trailing P/E ratio of 41.1x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 32% over the past three years.Reported Earnings • Feb 11Third quarter 2025 earnings released: EPS: ₹0.14 (vs ₹0.09 in 3Q 2024)Third quarter 2025 results: EPS: ₹0.14 (up from ₹0.09 in 3Q 2024). Revenue: ₹1.32b (up 102% from 3Q 2024). Net income: ₹130.0m (up 86% from 3Q 2024). Profit margin: 9.9% (in line with 3Q 2024). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.お知らせ • Feb 03Syncom Formulations (India) Limited to Report Q3, 2025 Results on Feb 12, 2025Syncom Formulations (India) Limited announced that they will report Q3, 2025 results on Feb 12, 2025Reported Earnings • Nov 12Second quarter 2025 earnings released: EPS: ₹0.16 (vs ₹0.08 in 2Q 2024)Second quarter 2025 results: EPS: ₹0.16 (up from ₹0.08 in 2Q 2024). Revenue: ₹1.06b (up 67% from 2Q 2024). Net income: ₹111.1m (up 71% from 2Q 2024). Profit margin: 10% (in line with 2Q 2024). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Nov 05Syncom Formulations (India) Limited to Report Q2, 2025 Results on Nov 11, 2024Syncom Formulations (India) Limited announced that they will report Q2, 2025 results on Nov 11, 2024Valuation Update With 7 Day Price Move • Sep 19Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹22.24, the stock trades at a trailing P/E ratio of 73.2x. Average trailing P/E is 42x in the Pharmaceuticals industry in India. Total returns to shareholders of 204% over the past three years.Valuation Update With 7 Day Price Move • Aug 21Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹19.10, the stock trades at a trailing P/E ratio of 62.9x. Average trailing P/E is 37x in the Pharmaceuticals industry in India. Total returns to shareholders of 190% over the past three years.お知らせ • Aug 13Syncom Formulations (India) Limited, Annual General Meeting, Sep 30, 2024Syncom Formulations (India) Limited, Annual General Meeting, Sep 30, 2024, at 14:00 Indian Standard Time.Reported Earnings • Aug 13First quarter 2025 earnings released: EPS: ₹0.11 (vs ₹0.07 in 1Q 2024)First quarter 2025 results: EPS: ₹0.11 (up from ₹0.07 in 1Q 2024). Revenue: ₹885.9m (up 48% from 1Q 2024). Net income: ₹76.3m (up 74% from 1Q 2024). Profit margin: 8.6% (up from 7.3% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 34% per year, which means it is well ahead of earnings.お知らせ • Aug 02Syncom Formulations (India) Limited to Report Q1, 2025 Results on Aug 12, 2024Syncom Formulations (India) Limited announced that they will report Q1, 2025 results on Aug 12, 2024Valuation Update With 7 Day Price Move • Jul 15Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹16.01, the stock trades at a trailing P/E ratio of 59.5x. Average trailing P/E is 35x in the Pharmaceuticals industry in India. Total returns to shareholders of 94% over the past three years.Reported Earnings • May 19Full year 2024 earnings released: EPS: ₹0.34 (vs ₹0.22 in FY 2023)Full year 2024 results: EPS: ₹0.34 (up from ₹0.22 in FY 2023). Revenue: ₹2.77b (up 24% from FY 2023). Net income: ₹253.1m (up 26% from FY 2023). Profit margin: 9.1% (up from 8.9% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Apr 03Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹12.92, the stock trades at a trailing P/E ratio of 46x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 321% over the past three years.お知らせ • Mar 29Syncom Formulations (India) Limited Announces Board ChangesSyncom Formulations (India) Limited announced that tenure completion of Shri Vinod Kumar Kabra, Shri Krishna Das Neema and Shri Praveen Jindal Independent Director(s) of the Company appointed w.e.f., 1 April, 2014 for a tenure of five (5) year and further were re-appointed w.e.f. 1 April, 2019 for further tenure of five (5) year in the category of Non-Executive Independent Directors of the company w.e.f. close of working hour of 31 March, 2024.Reported Earnings • Feb 15Third quarter 2024 earnings released: EPS: ₹0.09 (vs ₹0.06 in 3Q 2023)Third quarter 2024 results: EPS: ₹0.09 (up from ₹0.06 in 3Q 2023). Revenue: ₹696.9m (up 22% from 3Q 2023). Net income: ₹70.0m (up 69% from 3Q 2023). Profit margin: 10.0% (up from 7.2% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 65% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Dec 26Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹14.13, the stock trades at a trailing P/E ratio of 56.5x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 326% over the past three years.Valuation Update With 7 Day Price Move • Nov 23Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₹12.65, the stock trades at a trailing P/E ratio of 50.6x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 538% over the past three years.Reported Earnings • Nov 11Second quarter 2024 earnings released: EPS: ₹0.08 (vs ₹0.06 in 2Q 2023)Second quarter 2024 results: EPS: ₹0.08 (up from ₹0.06 in 2Q 2023). Revenue: ₹678.4m (up 25% from 2Q 2023). Net income: ₹65.1m (up 81% from 2Q 2023). Profit margin: 9.6% (up from 6.6% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 76% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Nov 09Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹10.30, the stock trades at a trailing P/E ratio of 47x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 515% over the past three years.お知らせ • Sep 05+ 2 more updatesSyncom Formulations (India) Limited to Report Q3, 2024 Results on Feb 14, 2024Syncom Formulations (India) Limited announced that they will report Q3, 2024 results on Feb 14, 2024お知らせ • Aug 15Syncom Formulations (India) Limited, Annual General Meeting, Sep 26, 2023Syncom Formulations (India) Limited, Annual General Meeting, Sep 26, 2023, at 15:00 Indian Standard Time.Reported Earnings • Aug 15First quarter 2024 earnings releasedFirst quarter 2024 results: EPS: ₹0.07. Revenue: ₹617.1m (up 20% from 1Q 2023). Net income: ₹44.0m (up 14% from 1Q 2023). Profit margin: 7.1% (down from 7.5% in 1Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 71% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Aug 07Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹9.27, the stock trades at a trailing P/E ratio of 43.4x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 379% over the past three years.お知らせ • Aug 04Syncom Formulations (India) Limited to Report Q1, 2024 Results on Aug 14, 2023Syncom Formulations (India) Limited announced that they will report Q1, 2024 results on Aug 14, 2023Reported Earnings • Jun 02Full year 2023 earnings released: EPS: ₹0.24 (vs ₹0.24 in FY 2022)Full year 2023 results: EPS: ₹0.24. Revenue: ₹2.39b (up 8.7% from FY 2022). Net income: ₹200.7m (up 1.4% from FY 2022). Profit margin: 8.4% (down from 9.0% in FY 2022). The decrease in margin was driven by higher expenses.Valuation Update With 7 Day Price Move • Mar 28Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹4.99, the stock trades at a trailing P/E ratio of 28.7x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 595% over the past three years.Reported Earnings • Feb 14Third quarter 2023 earnings released: EPS: ₹0.06 (vs ₹0.07 in 3Q 2022)Third quarter 2023 results: EPS: ₹0.06. Revenue: ₹593.6m (up 3.7% from 3Q 2022). Net income: ₹41.4m (up 3.3% from 3Q 2022). Profit margin: 7.0% (in line with 3Q 2022).お知らせ • Feb 02Syncom Formulations (India) Limited to Report Q3, 2023 Results on Feb 13, 2023Syncom Formulations (India) Limited announced that they will report Q3, 2023 results on Feb 13, 2023Valuation Update With 7 Day Price Move • Dec 23Investor sentiment improved over the past weekAfter last week's 24% share price gain to ₹9.74, the stock trades at a trailing P/E ratio of 56.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 1,221% over the past three years.Reported Earnings • Nov 19Second quarter 2023 earnings released: EPS: ₹0.06 (vs ₹0.06 in 2Q 2022)Second quarter 2023 results: EPS: ₹0.06 (in line with 2Q 2022). Revenue: ₹544.9m (up 2.9% from 2Q 2022). Net income: ₹35.9m (down 36% from 2Q 2022). Profit margin: 6.6% (down from 11% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 128% per year, which means it is tracking significantly ahead of earnings growth.Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. No experienced directors. 6 highly experienced directors. Additional Non-Executive Independent Woman Director Ruchi Jindal was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Sep 20Syncom Formulations (India) Limited Approves the Declaration of Dividend for the Financial Year Ended 31 March 2022Syncom Formulations (India) Limited at its AGM held on September 19, 2022, approved the declaration of dividend on equity shares INR 0.03 (3.00%) on the equity share of INR 1 each of the Company for the Financial Year ended 31 March, 2022 by way of an Ordinary Resolution.Upcoming Dividend • Sep 02Upcoming dividend of ₹0.03 per shareEligible shareholders must have bought the stock before 09 September 2022. Payment date: 19 October 2022. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.6%). Lower than average of industry peers (1.0%).Reported Earnings • Aug 18First quarter 2023 earnings released: EPS: ₹0.03 (vs ₹0.08 in 1Q 2022)First quarter 2023 results: EPS: ₹0.03 (down from ₹0.08 in 1Q 2022). Revenue: ₹543.8m (up 6.1% from 1Q 2022). Net income: ₹38.7m (down 28% from 1Q 2022). Profit margin: 7.1% (down from 11% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 126% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Aug 16Syncom Formulations (India) Limited, Annual General Meeting, Sep 19, 2022Syncom Formulations (India) Limited, Annual General Meeting, Sep 19, 2022, at 14:00 Indian Standard Time. Location: 7, Niraj Industrial Estate. Off Mahakali Caves Road Andhcri (East) Mumbai India Agenda: To receive, consider, approve and adopt the Standalone Audited Financial statements containing the balance Sheet as at 31st March, 2022, the Statement of Profit & Loss and Cash Flow and Changes in Equity. for the financial year ended 31st March, 2022 and the Reports of the Boards and Auditors thereon as on that date; to declare dividend on equity shares of the Company for the Financial Year ended March 31, 2022; to appoint a director; to consider re-appointment of M/s. Sanjay Mehta & Associates, Chartered Accountants as the Statutory Auditors of the Company; to ratify the remuneration of Cost Auditor of the company for the year 2022-23; and to consider other related matters.Valuation Update With 7 Day Price Move • Jul 21Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₹9.58, the stock trades at a trailing P/E ratio of 45.5x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 1,083% over the past three years.お知らせ • Jun 29Syncom Formulations (India) Limited Appoints Ruchi Jindal as an Additional DirectorSyncom Formulations (India) Limited at its Board Meeting held on June 28, 2022, the Board has upon the recommendation of the Nomination and Remuneration Committee has appointed Mrs. Ruchi Jindal as an Additional Director (Woman Independent Director) on the Board of Directors till the date of next General Meeting or within 3 months whichever may be earlier and consequently there is a change in Directors pursuant to such appointment. Mrs. Ruchi Jindal is' a chartered accountants and has working experience of more than five years in Baidyanath Group of Companies and has managed finance, Accounts and Internal Management. She is currently owning the Central India's Biggest and top l0 in e- Commerce platform "Premium Bike Accessories Showroom".Buying Opportunity • Jun 20Now 25% undervalued after recent price dropOver the last 90 days, the stock is down 43%. The fair value is estimated to be ₹8.46, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.8% over the last 3 years. Earnings per share has grown by 31%.Valuation Update With 7 Day Price Move • Jun 16Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹7.32, the stock trades at a trailing P/E ratio of 34.8x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 732% over the past three years.Reported Earnings • May 24Full year 2022 earnings released: EPS: ₹0.26 (vs ₹0.38 in FY 2021)Full year 2022 results: EPS: ₹0.26 (down from ₹0.38 in FY 2021). Revenue: ₹2.20b (down 10% from FY 2021). Net income: ₹197.9m (down 32% from FY 2021). Profit margin: 9.0% (down from 12% in FY 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has increased by 100% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • May 10Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹9.09, the stock trades at a trailing P/E ratio of 35.7x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 857% over the past three years.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 5 highly experienced directors. Whole Time Director Rinki Bankda was the last director to join the board, commencing their role in 2014. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹12.47, the stock trades at a trailing P/E ratio of 48.9x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 1,013% over the past three years.Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improved over the past weekAfter last week's 25% share price gain to ₹13.00, the stock trades at a trailing P/E ratio of 51x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 1,061% over the past three years.Reported Earnings • Feb 17Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹0.07 (down from ₹0.13 in 3Q 2021). Revenue: ₹572.3m (down 32% from 3Q 2021). Net income: ₹40.1m (down 60% from 3Q 2021). Profit margin: 7.0% (down from 12% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has increased by 128% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Feb 17Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to ₹11.75, the stock trades at a trailing P/E ratio of 34.8x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 1,087% over the past three years.Valuation Update With 7 Day Price Move • Dec 29Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₹11.40, the stock trades at a trailing P/E ratio of 33.8x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 1,153% over the past three years.Valuation Update With 7 Day Price Move • Oct 07Investor sentiment improved over the past weekAfter last week's 32% share price gain to ₹9.34, the stock trades at a trailing P/E ratio of 24.5x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 1,082% over the past three years.Valuation Update With 7 Day Price Move • Sep 22Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹6.99, the stock trades at a trailing P/E ratio of 17.5x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 636% over the past three years.Valuation Update With 7 Day Price Move • Aug 20Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₹5.97, the stock trades at a trailing P/E ratio of 15.7x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 463% over the past three years.Valuation Update With 7 Day Price Move • Jul 29Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₹7.02, the stock trades at a trailing P/E ratio of 18.5x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 588% over the past three years.Reported Earnings • Jul 04Full year 2021 earnings released: EPS ₹0.38 (vs ₹0.17 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹2.45b (up 19% from FY 2020). Net income: ₹291.7m (up 105% from FY 2020). Profit margin: 12% (up from 6.9% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has increased by 96% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Apr 14Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₹3.72, the stock trades at a trailing P/E ratio of 11.5x. Average trailing P/E is 19x in the Pharmaceuticals industry in India. Total returns to shareholders of 180% over the past three years.Is New 90 Day High Low • Mar 14New 90-day low: ₹3.09The company is down 3.0% from its price of ₹3.18 on 14 December 2020. The Indian market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period.Reported Earnings • Feb 17Third quarter 2021 earnings released: EPS ₹0.13 (vs ₹0.04 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹841.7m (up 61% from 3Q 2020). Net income: ₹100.2m (up 186% from 3Q 2020). Profit margin: 12% (up from 6.7% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth.お知らせ • Feb 04Syncom Formulations (India) Limited to Report Q3, 2021 Results on Feb 12, 2021Syncom Formulations (India) Limited announced that they will report Q3, 2021 results on Feb 12, 2021Is New 90 Day High Low • Jan 06New 90-day high: ₹3.72The company is up 140% from its price of ₹1.55 on 08 October 2020. The Indian market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 8.0% over the same period.お知らせ • Dec 20Syncom Formulations (India) Limited announced that it expects to receive INR 100.787496 million in fundingSyncom Formulations (India) Limited (BSE:524470) announced a private placement of up to 159,347,820 prepaid warrants at INR 0.6325 per warrant for gross proceeds of up to INR 100,787,496.15 on December 18, 2020. The round will include participation from promoter and promoter group on preferential basis. The company will receive 25% of the total amount, which is INR 100,787,496.15 as upfront payment at the time of allotment of warrants and the remaining 75% will be received within 18 months. The warrants will be exercisable into common shares at INR 1.8975 per share in one or more tranches within a period of 18 months. Each common share to be issued will have a par value of INR 1. The transaction is subject to shareholder’s approval in extra ordinary general meeting to be held on January 12, 2021. The board of directors of the company approved the transaction.Valuation Update With 7 Day Price Move • Dec 02Market bids up stock over the past weekAfter last week's 20% share price gain to ₹2.28, the stock is trading at a trailing P/E ratio of 12.4x, up from the previous P/E ratio of 10.4x. This compares to an average P/E of 22x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 14%.Is New 90 Day High Low • Nov 17New 90-day high: ₹1.93The company is up 4.0% from its price of ₹1.85 on 19 August 2020. The Indian market is up 9.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 1.0% over the same period.Valuation Update With 7 Day Price Move • Nov 13Market bids up stock over the past weekAfter last week's 21% share price gain to ₹1.76, the stock is trading at a trailing P/E ratio of 9.6x, up from the previous P/E ratio of 8x. This compares to an average P/E of 22x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 7.3%.Is New 90 Day High Low • Oct 15New 90-day low: ₹1.42The company is down 14% from its price of ₹1.66 on 17 July 2020. The Indian market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 14% over the same period.お知らせ • Jul 05Syncom Formulations (India) Limited to Report Q4, 2020 Results on Jun 30, 2020Syncom Formulations (India) Limited announced that they will report Q4, 2020 results on Jun 30, 2020株主還元524470IN PharmaceuticalsIN 市場7D12.9%0.004%2.0%1Y-27.3%10.7%0.4%株主還元を見る業界別リターン: 524470過去 1 年間で10.7 % の収益を上げたIndian Pharmaceuticals業界を下回りました。リターン対市場: 524470は、過去 1 年間で0.4 % のリターンを上げたIndian市場を下回りました。価格変動Is 524470's price volatile compared to industry and market?524470 volatility524470 Average Weekly Movement7.2%Pharmaceuticals Industry Average Movement6.8%Market Average Movement7.2%10% most volatile stocks in IN Market10.2%10% least volatile stocks in IN Market4.8%安定した株価: 524470 、 Indian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 524470の 週次ボラティリティ ( 7% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1988744Vijay Bankdawww.syncomformulations.comSyncom Formulations (India) Limited はインドで医薬品製剤の製造、販売、マーケティングを行っている。医薬品・製剤の製造・販売、商品取引、不動産賃貸の事業を行っている。抗生物質・抗感染症薬、駆虫薬、抗マラリア薬、心臓薬、皮膚薬、胃腸薬、婦人薬、眼科薬、整形外科薬、小児科薬などの製剤を提供している。また、クラタスブランドでライフケア、進化、正しい栄養製品を提供している。また、商品取引や不動産賃貸も行っている。製品の輸出も行っている。同社は、錠剤、カプセル剤、軟膏剤、注射剤、液剤、経口剤、発泡剤など様々な剤形の医薬品を提供している。Syncom Formulations (India) Limited は1988年に設立され、インド、インドールに拠点を置く。もっと見るSyncom Formulations (India) Limited 基礎のまとめSyncom Formulations (India) の収益と売上を時価総額と比較するとどうか。524470 基礎統計学時価総額₹15.06b収益（TTM）₹764.38m売上高(TTM)₹5.21b19.7xPER（株価収益率2.9xP/Sレシオ524470 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計524470 損益計算書（TTM）収益₹5.21b売上原価₹2.84b売上総利益₹2.36bその他の費用₹1.60b収益₹764.38m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）0.81グロス・マージン45.39%純利益率14.69%有利子負債／自己資本比率0.4%524470 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/26 15:37終値2026/05/26 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Syncom Formulations (India) Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • May 23Full year 2026 earnings released: EPS: ₹0.81 (vs ₹0.53 in FY 2025)Full year 2026 results: EPS: ₹0.81 (up from ₹0.53 in FY 2025). Revenue: ₹5.21b (up 12% from FY 2025). Net income: ₹764.4m (up 55% from FY 2025). Profit margin: 15% (up from 11% in FY 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹12.25, the stock trades at a trailing P/E ratio of 16.7x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 88% over the past three years.
Reported Earnings • Feb 14Third quarter 2026 earnings released: EPS: ₹0.23 (vs ₹0.14 in 3Q 2025)Third quarter 2026 results: EPS: ₹0.23 (up from ₹0.14 in 3Q 2025). Revenue: ₹1.21b (down 5.4% from 3Q 2025). Net income: ₹189.1m (up 45% from 3Q 2025). Profit margin: 16% (up from 10% in 3Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Nov 13Second quarter 2026 earnings released: EPS: ₹0.18 (vs ₹0.16 in 2Q 2025)Second quarter 2026 results: EPS: ₹0.18 (up from ₹0.16 in 2Q 2025). Revenue: ₹1.27b (up 24% from 2Q 2025). Net income: ₹166.0m (up 49% from 2Q 2025). Profit margin: 13% (up from 11% in 2Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 26% per year, which means it is significantly lagging earnings growth.
お知らせ • Oct 01Syncom Formulations (India) Limited Approves Appointment of Shri Ankit Kedarmal as Executive ChairmanSyncom Formulations (India) Limited at its AGM held on September 29, 2025, approved appointment of Shri Ankit Kedarmal as Executive Chairman and to approve the remuneration payable to him.
お知らせ • Sep 04+ 2 more updatesSyncom Formulations (India) Limited to Report Q3, 2026 Results on Feb 14, 2026Syncom Formulations (India) Limited announced that they will report Q3, 2026 results on Feb 14, 2026
Reported Earnings • May 23Full year 2026 earnings released: EPS: ₹0.81 (vs ₹0.53 in FY 2025)Full year 2026 results: EPS: ₹0.81 (up from ₹0.53 in FY 2025). Revenue: ₹5.21b (up 12% from FY 2025). Net income: ₹764.4m (up 55% from FY 2025). Profit margin: 15% (up from 11% in FY 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹12.25, the stock trades at a trailing P/E ratio of 16.7x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 88% over the past three years.
Reported Earnings • Feb 14Third quarter 2026 earnings released: EPS: ₹0.23 (vs ₹0.14 in 3Q 2025)Third quarter 2026 results: EPS: ₹0.23 (up from ₹0.14 in 3Q 2025). Revenue: ₹1.21b (down 5.4% from 3Q 2025). Net income: ₹189.1m (up 45% from 3Q 2025). Profit margin: 16% (up from 10% in 3Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Nov 13Second quarter 2026 earnings released: EPS: ₹0.18 (vs ₹0.16 in 2Q 2025)Second quarter 2026 results: EPS: ₹0.18 (up from ₹0.16 in 2Q 2025). Revenue: ₹1.27b (up 24% from 2Q 2025). Net income: ₹166.0m (up 49% from 2Q 2025). Profit margin: 13% (up from 11% in 2Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 26% per year, which means it is significantly lagging earnings growth.
お知らせ • Oct 01Syncom Formulations (India) Limited Approves Appointment of Shri Ankit Kedarmal as Executive ChairmanSyncom Formulations (India) Limited at its AGM held on September 29, 2025, approved appointment of Shri Ankit Kedarmal as Executive Chairman and to approve the remuneration payable to him.
お知らせ • Sep 04+ 2 more updatesSyncom Formulations (India) Limited to Report Q3, 2026 Results on Feb 14, 2026Syncom Formulations (India) Limited announced that they will report Q3, 2026 results on Feb 14, 2026
お知らせ • Aug 11Syncom Formulations (India) Limited, Annual General Meeting, Sep 29, 2025Syncom Formulations (India) Limited, Annual General Meeting, Sep 29, 2025, at 14:00 Indian Standard Time.
Reported Earnings • Aug 09First quarter 2026 earnings released: EPS: ₹0.21 (vs ₹0.11 in 1Q 2025)First quarter 2026 results: EPS: ₹0.21 (up from ₹0.11 in 1Q 2025). Revenue: ₹1.23b (up 41% from 1Q 2025). Net income: ₹157.5m (up 106% from 1Q 2025). Profit margin: 13% (up from 8.7% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 26% per year, which means it is significantly lagging earnings growth.
お知らせ • Aug 08+ 1 more updateSyncom Formulations (India) Limited Announces CFO ChangesSyncom Formulations (India) Limited announced that at its board meeting held on August 08, 2025, noted and accepted the resignation of Shri Ankit Kedarnal Bankda from the position of Chief Financial Officer (CFO), with effect from the close of business hours on August 08, 2025. The company approved the appointment of Shri Rahul Vijay Bankda as Chief Financial Officer (CFO) of the Company, with effect from August 09, 2025.
お知らせ • Aug 02Syncom Formulations (India) Limited to Report Q1, 2026 Results on Aug 08, 2025Syncom Formulations (India) Limited announced that they will report Q1, 2026 results on Aug 08, 2025
New Risk • May 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Reported Earnings • May 21Full year 2025 earnings released: EPS: ₹0.57 (vs ₹0.27 in FY 2024)Full year 2025 results: EPS: ₹0.57 (up from ₹0.27 in FY 2024). Revenue: ₹4.82b (up 83% from FY 2024). Net income: ₹494.3m (up 95% from FY 2024). Profit margin: 10% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 31% per year whereas the company’s share price has increased by 33% per year.
Valuation Update With 7 Day Price Move • May 16Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹17.51, the stock trades at a trailing P/E ratio of 42x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 92% over the past three years.
お知らせ • May 13Syncom Formulations (India) Limited to Report Q4, 2025 Results on May 19, 2025Syncom Formulations (India) Limited announced that they will report Q4, 2025 results on May 19, 2025
Valuation Update With 7 Day Price Move • Mar 24Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹18.25, the stock trades at a trailing P/E ratio of 43.8x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 67% over the past three years.
Valuation Update With 7 Day Price Move • Mar 10Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹17.12, the stock trades at a trailing P/E ratio of 41.1x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 32% over the past three years.
Reported Earnings • Feb 11Third quarter 2025 earnings released: EPS: ₹0.14 (vs ₹0.09 in 3Q 2024)Third quarter 2025 results: EPS: ₹0.14 (up from ₹0.09 in 3Q 2024). Revenue: ₹1.32b (up 102% from 3Q 2024). Net income: ₹130.0m (up 86% from 3Q 2024). Profit margin: 9.9% (in line with 3Q 2024). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.
お知らせ • Feb 03Syncom Formulations (India) Limited to Report Q3, 2025 Results on Feb 12, 2025Syncom Formulations (India) Limited announced that they will report Q3, 2025 results on Feb 12, 2025
Reported Earnings • Nov 12Second quarter 2025 earnings released: EPS: ₹0.16 (vs ₹0.08 in 2Q 2024)Second quarter 2025 results: EPS: ₹0.16 (up from ₹0.08 in 2Q 2024). Revenue: ₹1.06b (up 67% from 2Q 2024). Net income: ₹111.1m (up 71% from 2Q 2024). Profit margin: 10% (in line with 2Q 2024). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Nov 05Syncom Formulations (India) Limited to Report Q2, 2025 Results on Nov 11, 2024Syncom Formulations (India) Limited announced that they will report Q2, 2025 results on Nov 11, 2024
Valuation Update With 7 Day Price Move • Sep 19Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹22.24, the stock trades at a trailing P/E ratio of 73.2x. Average trailing P/E is 42x in the Pharmaceuticals industry in India. Total returns to shareholders of 204% over the past three years.
Valuation Update With 7 Day Price Move • Aug 21Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹19.10, the stock trades at a trailing P/E ratio of 62.9x. Average trailing P/E is 37x in the Pharmaceuticals industry in India. Total returns to shareholders of 190% over the past three years.
お知らせ • Aug 13Syncom Formulations (India) Limited, Annual General Meeting, Sep 30, 2024Syncom Formulations (India) Limited, Annual General Meeting, Sep 30, 2024, at 14:00 Indian Standard Time.
Reported Earnings • Aug 13First quarter 2025 earnings released: EPS: ₹0.11 (vs ₹0.07 in 1Q 2024)First quarter 2025 results: EPS: ₹0.11 (up from ₹0.07 in 1Q 2024). Revenue: ₹885.9m (up 48% from 1Q 2024). Net income: ₹76.3m (up 74% from 1Q 2024). Profit margin: 8.6% (up from 7.3% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 34% per year, which means it is well ahead of earnings.
お知らせ • Aug 02Syncom Formulations (India) Limited to Report Q1, 2025 Results on Aug 12, 2024Syncom Formulations (India) Limited announced that they will report Q1, 2025 results on Aug 12, 2024
Valuation Update With 7 Day Price Move • Jul 15Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹16.01, the stock trades at a trailing P/E ratio of 59.5x. Average trailing P/E is 35x in the Pharmaceuticals industry in India. Total returns to shareholders of 94% over the past three years.
Reported Earnings • May 19Full year 2024 earnings released: EPS: ₹0.34 (vs ₹0.22 in FY 2023)Full year 2024 results: EPS: ₹0.34 (up from ₹0.22 in FY 2023). Revenue: ₹2.77b (up 24% from FY 2023). Net income: ₹253.1m (up 26% from FY 2023). Profit margin: 9.1% (up from 8.9% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Apr 03Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹12.92, the stock trades at a trailing P/E ratio of 46x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 321% over the past three years.
お知らせ • Mar 29Syncom Formulations (India) Limited Announces Board ChangesSyncom Formulations (India) Limited announced that tenure completion of Shri Vinod Kumar Kabra, Shri Krishna Das Neema and Shri Praveen Jindal Independent Director(s) of the Company appointed w.e.f., 1 April, 2014 for a tenure of five (5) year and further were re-appointed w.e.f. 1 April, 2019 for further tenure of five (5) year in the category of Non-Executive Independent Directors of the company w.e.f. close of working hour of 31 March, 2024.
Reported Earnings • Feb 15Third quarter 2024 earnings released: EPS: ₹0.09 (vs ₹0.06 in 3Q 2023)Third quarter 2024 results: EPS: ₹0.09 (up from ₹0.06 in 3Q 2023). Revenue: ₹696.9m (up 22% from 3Q 2023). Net income: ₹70.0m (up 69% from 3Q 2023). Profit margin: 10.0% (up from 7.2% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 65% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Dec 26Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹14.13, the stock trades at a trailing P/E ratio of 56.5x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 326% over the past three years.
Valuation Update With 7 Day Price Move • Nov 23Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₹12.65, the stock trades at a trailing P/E ratio of 50.6x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 538% over the past three years.
Reported Earnings • Nov 11Second quarter 2024 earnings released: EPS: ₹0.08 (vs ₹0.06 in 2Q 2023)Second quarter 2024 results: EPS: ₹0.08 (up from ₹0.06 in 2Q 2023). Revenue: ₹678.4m (up 25% from 2Q 2023). Net income: ₹65.1m (up 81% from 2Q 2023). Profit margin: 9.6% (up from 6.6% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 76% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Nov 09Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹10.30, the stock trades at a trailing P/E ratio of 47x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 515% over the past three years.
お知らせ • Sep 05+ 2 more updatesSyncom Formulations (India) Limited to Report Q3, 2024 Results on Feb 14, 2024Syncom Formulations (India) Limited announced that they will report Q3, 2024 results on Feb 14, 2024
お知らせ • Aug 15Syncom Formulations (India) Limited, Annual General Meeting, Sep 26, 2023Syncom Formulations (India) Limited, Annual General Meeting, Sep 26, 2023, at 15:00 Indian Standard Time.
Reported Earnings • Aug 15First quarter 2024 earnings releasedFirst quarter 2024 results: EPS: ₹0.07. Revenue: ₹617.1m (up 20% from 1Q 2023). Net income: ₹44.0m (up 14% from 1Q 2023). Profit margin: 7.1% (down from 7.5% in 1Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 71% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Aug 07Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹9.27, the stock trades at a trailing P/E ratio of 43.4x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 379% over the past three years.
お知らせ • Aug 04Syncom Formulations (India) Limited to Report Q1, 2024 Results on Aug 14, 2023Syncom Formulations (India) Limited announced that they will report Q1, 2024 results on Aug 14, 2023
Reported Earnings • Jun 02Full year 2023 earnings released: EPS: ₹0.24 (vs ₹0.24 in FY 2022)Full year 2023 results: EPS: ₹0.24. Revenue: ₹2.39b (up 8.7% from FY 2022). Net income: ₹200.7m (up 1.4% from FY 2022). Profit margin: 8.4% (down from 9.0% in FY 2022). The decrease in margin was driven by higher expenses.
Valuation Update With 7 Day Price Move • Mar 28Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹4.99, the stock trades at a trailing P/E ratio of 28.7x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 595% over the past three years.
Reported Earnings • Feb 14Third quarter 2023 earnings released: EPS: ₹0.06 (vs ₹0.07 in 3Q 2022)Third quarter 2023 results: EPS: ₹0.06. Revenue: ₹593.6m (up 3.7% from 3Q 2022). Net income: ₹41.4m (up 3.3% from 3Q 2022). Profit margin: 7.0% (in line with 3Q 2022).
お知らせ • Feb 02Syncom Formulations (India) Limited to Report Q3, 2023 Results on Feb 13, 2023Syncom Formulations (India) Limited announced that they will report Q3, 2023 results on Feb 13, 2023
Valuation Update With 7 Day Price Move • Dec 23Investor sentiment improved over the past weekAfter last week's 24% share price gain to ₹9.74, the stock trades at a trailing P/E ratio of 56.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 1,221% over the past three years.
Reported Earnings • Nov 19Second quarter 2023 earnings released: EPS: ₹0.06 (vs ₹0.06 in 2Q 2022)Second quarter 2023 results: EPS: ₹0.06 (in line with 2Q 2022). Revenue: ₹544.9m (up 2.9% from 2Q 2022). Net income: ₹35.9m (down 36% from 2Q 2022). Profit margin: 6.6% (down from 11% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 128% per year, which means it is tracking significantly ahead of earnings growth.
Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. No experienced directors. 6 highly experienced directors. Additional Non-Executive Independent Woman Director Ruchi Jindal was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 20Syncom Formulations (India) Limited Approves the Declaration of Dividend for the Financial Year Ended 31 March 2022Syncom Formulations (India) Limited at its AGM held on September 19, 2022, approved the declaration of dividend on equity shares INR 0.03 (3.00%) on the equity share of INR 1 each of the Company for the Financial Year ended 31 March, 2022 by way of an Ordinary Resolution.
Upcoming Dividend • Sep 02Upcoming dividend of ₹0.03 per shareEligible shareholders must have bought the stock before 09 September 2022. Payment date: 19 October 2022. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.6%). Lower than average of industry peers (1.0%).
Reported Earnings • Aug 18First quarter 2023 earnings released: EPS: ₹0.03 (vs ₹0.08 in 1Q 2022)First quarter 2023 results: EPS: ₹0.03 (down from ₹0.08 in 1Q 2022). Revenue: ₹543.8m (up 6.1% from 1Q 2022). Net income: ₹38.7m (down 28% from 1Q 2022). Profit margin: 7.1% (down from 11% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 126% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Aug 16Syncom Formulations (India) Limited, Annual General Meeting, Sep 19, 2022Syncom Formulations (India) Limited, Annual General Meeting, Sep 19, 2022, at 14:00 Indian Standard Time. Location: 7, Niraj Industrial Estate. Off Mahakali Caves Road Andhcri (East) Mumbai India Agenda: To receive, consider, approve and adopt the Standalone Audited Financial statements containing the balance Sheet as at 31st March, 2022, the Statement of Profit & Loss and Cash Flow and Changes in Equity. for the financial year ended 31st March, 2022 and the Reports of the Boards and Auditors thereon as on that date; to declare dividend on equity shares of the Company for the Financial Year ended March 31, 2022; to appoint a director; to consider re-appointment of M/s. Sanjay Mehta & Associates, Chartered Accountants as the Statutory Auditors of the Company; to ratify the remuneration of Cost Auditor of the company for the year 2022-23; and to consider other related matters.
Valuation Update With 7 Day Price Move • Jul 21Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₹9.58, the stock trades at a trailing P/E ratio of 45.5x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 1,083% over the past three years.
お知らせ • Jun 29Syncom Formulations (India) Limited Appoints Ruchi Jindal as an Additional DirectorSyncom Formulations (India) Limited at its Board Meeting held on June 28, 2022, the Board has upon the recommendation of the Nomination and Remuneration Committee has appointed Mrs. Ruchi Jindal as an Additional Director (Woman Independent Director) on the Board of Directors till the date of next General Meeting or within 3 months whichever may be earlier and consequently there is a change in Directors pursuant to such appointment. Mrs. Ruchi Jindal is' a chartered accountants and has working experience of more than five years in Baidyanath Group of Companies and has managed finance, Accounts and Internal Management. She is currently owning the Central India's Biggest and top l0 in e- Commerce platform "Premium Bike Accessories Showroom".
Buying Opportunity • Jun 20Now 25% undervalued after recent price dropOver the last 90 days, the stock is down 43%. The fair value is estimated to be ₹8.46, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.8% over the last 3 years. Earnings per share has grown by 31%.
Valuation Update With 7 Day Price Move • Jun 16Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹7.32, the stock trades at a trailing P/E ratio of 34.8x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 732% over the past three years.
Reported Earnings • May 24Full year 2022 earnings released: EPS: ₹0.26 (vs ₹0.38 in FY 2021)Full year 2022 results: EPS: ₹0.26 (down from ₹0.38 in FY 2021). Revenue: ₹2.20b (down 10% from FY 2021). Net income: ₹197.9m (down 32% from FY 2021). Profit margin: 9.0% (down from 12% in FY 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has increased by 100% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • May 10Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₹9.09, the stock trades at a trailing P/E ratio of 35.7x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 857% over the past three years.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 5 highly experienced directors. Whole Time Director Rinki Bankda was the last director to join the board, commencing their role in 2014. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹12.47, the stock trades at a trailing P/E ratio of 48.9x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 1,013% over the past three years.
Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improved over the past weekAfter last week's 25% share price gain to ₹13.00, the stock trades at a trailing P/E ratio of 51x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 1,061% over the past three years.
Reported Earnings • Feb 17Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹0.07 (down from ₹0.13 in 3Q 2021). Revenue: ₹572.3m (down 32% from 3Q 2021). Net income: ₹40.1m (down 60% from 3Q 2021). Profit margin: 7.0% (down from 12% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has increased by 128% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Feb 17Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to ₹11.75, the stock trades at a trailing P/E ratio of 34.8x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 1,087% over the past three years.
Valuation Update With 7 Day Price Move • Dec 29Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₹11.40, the stock trades at a trailing P/E ratio of 33.8x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 1,153% over the past three years.
Valuation Update With 7 Day Price Move • Oct 07Investor sentiment improved over the past weekAfter last week's 32% share price gain to ₹9.34, the stock trades at a trailing P/E ratio of 24.5x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 1,082% over the past three years.
Valuation Update With 7 Day Price Move • Sep 22Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹6.99, the stock trades at a trailing P/E ratio of 17.5x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 636% over the past three years.
Valuation Update With 7 Day Price Move • Aug 20Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₹5.97, the stock trades at a trailing P/E ratio of 15.7x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 463% over the past three years.
Valuation Update With 7 Day Price Move • Jul 29Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₹7.02, the stock trades at a trailing P/E ratio of 18.5x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 588% over the past three years.
Reported Earnings • Jul 04Full year 2021 earnings released: EPS ₹0.38 (vs ₹0.17 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹2.45b (up 19% from FY 2020). Net income: ₹291.7m (up 105% from FY 2020). Profit margin: 12% (up from 6.9% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has increased by 96% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Apr 14Investor sentiment improved over the past weekAfter last week's 21% share price gain to ₹3.72, the stock trades at a trailing P/E ratio of 11.5x. Average trailing P/E is 19x in the Pharmaceuticals industry in India. Total returns to shareholders of 180% over the past three years.
Is New 90 Day High Low • Mar 14New 90-day low: ₹3.09The company is down 3.0% from its price of ₹3.18 on 14 December 2020. The Indian market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period.
Reported Earnings • Feb 17Third quarter 2021 earnings released: EPS ₹0.13 (vs ₹0.04 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹841.7m (up 61% from 3Q 2020). Net income: ₹100.2m (up 186% from 3Q 2020). Profit margin: 12% (up from 6.7% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth.
お知らせ • Feb 04Syncom Formulations (India) Limited to Report Q3, 2021 Results on Feb 12, 2021Syncom Formulations (India) Limited announced that they will report Q3, 2021 results on Feb 12, 2021
Is New 90 Day High Low • Jan 06New 90-day high: ₹3.72The company is up 140% from its price of ₹1.55 on 08 October 2020. The Indian market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 8.0% over the same period.
お知らせ • Dec 20Syncom Formulations (India) Limited announced that it expects to receive INR 100.787496 million in fundingSyncom Formulations (India) Limited (BSE:524470) announced a private placement of up to 159,347,820 prepaid warrants at INR 0.6325 per warrant for gross proceeds of up to INR 100,787,496.15 on December 18, 2020. The round will include participation from promoter and promoter group on preferential basis. The company will receive 25% of the total amount, which is INR 100,787,496.15 as upfront payment at the time of allotment of warrants and the remaining 75% will be received within 18 months. The warrants will be exercisable into common shares at INR 1.8975 per share in one or more tranches within a period of 18 months. Each common share to be issued will have a par value of INR 1. The transaction is subject to shareholder’s approval in extra ordinary general meeting to be held on January 12, 2021. The board of directors of the company approved the transaction.
Valuation Update With 7 Day Price Move • Dec 02Market bids up stock over the past weekAfter last week's 20% share price gain to ₹2.28, the stock is trading at a trailing P/E ratio of 12.4x, up from the previous P/E ratio of 10.4x. This compares to an average P/E of 22x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 14%.
Is New 90 Day High Low • Nov 17New 90-day high: ₹1.93The company is up 4.0% from its price of ₹1.85 on 19 August 2020. The Indian market is up 9.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 1.0% over the same period.
Valuation Update With 7 Day Price Move • Nov 13Market bids up stock over the past weekAfter last week's 21% share price gain to ₹1.76, the stock is trading at a trailing P/E ratio of 9.6x, up from the previous P/E ratio of 8x. This compares to an average P/E of 22x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 7.3%.
Is New 90 Day High Low • Oct 15New 90-day low: ₹1.42The company is down 14% from its price of ₹1.66 on 17 July 2020. The Indian market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 14% over the same period.
お知らせ • Jul 05Syncom Formulations (India) Limited to Report Q4, 2020 Results on Jun 30, 2020Syncom Formulations (India) Limited announced that they will report Q4, 2020 results on Jun 30, 2020
